{"title":"First week of social lockdown versus medical care against COVID-19 - with special reference to India","authors":"Kabita Das, B. Paital","doi":"10.5530/ctbp.2020.2.20","DOIUrl":null,"url":null,"abstract":"The disease caused by Coronavirus (CoV) is called as Coronavirus Disease (COVID-19). It became pandemic in 210 countries and rolling data indicate that 2,606,635individuals are infected with the deadly pandemic disease and 713,812 have recovered, while, 182,114 have lost their lives. Although, few drugs namely Chloroquine, Hydr oxychl or oqui ne and Azi t hr omyci n, Tocilizumab, Lopinavir; Ritonavir and Tocilizumab are recommended on contextual basis for the treatment of COVID-19, the world is still waiting to come up with a specific vaccine or medicine to combat the disease. Without a specific medicine, countries such as Italy, USA, Spain and France, withthe most advanced health care systems are unsuccessful to control both the infection and death rate under COVID-19 infection. India being the world’s 2 ndlargest populous country, where, the health care system is under developed, with major portion of people live less-hygienic life, has contracted the disease at a slower rate as compared to the above countries. India has achieved this through employing social distancing by following a strict lockdown. This article is focused on social distancing of India and the kind of social interaction that can be adapted by people during lockdown.","PeriodicalId":10980,"journal":{"name":"Current Trends in Biotechnology and Pharmacy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"22","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Trends in Biotechnology and Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5530/ctbp.2020.2.20","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 22
Abstract
The disease caused by Coronavirus (CoV) is called as Coronavirus Disease (COVID-19). It became pandemic in 210 countries and rolling data indicate that 2,606,635individuals are infected with the deadly pandemic disease and 713,812 have recovered, while, 182,114 have lost their lives. Although, few drugs namely Chloroquine, Hydr oxychl or oqui ne and Azi t hr omyci n, Tocilizumab, Lopinavir; Ritonavir and Tocilizumab are recommended on contextual basis for the treatment of COVID-19, the world is still waiting to come up with a specific vaccine or medicine to combat the disease. Without a specific medicine, countries such as Italy, USA, Spain and France, withthe most advanced health care systems are unsuccessful to control both the infection and death rate under COVID-19 infection. India being the world’s 2 ndlargest populous country, where, the health care system is under developed, with major portion of people live less-hygienic life, has contracted the disease at a slower rate as compared to the above countries. India has achieved this through employing social distancing by following a strict lockdown. This article is focused on social distancing of India and the kind of social interaction that can be adapted by people during lockdown.
期刊介绍:
The Association of Biotechnology and Pharmacy (ABAP) will be useful to form a forum for scientists so that they can bring together to discuss and find scientific solutions to the problems of society. The annual meetings will help the members to share their knowledge and publish their research knowledge particularly by members and fellows of the Association and special care will be taken to provide an opportunity for young scientists. Besides this the association is planned to organize symposia, seminars and workshops on current developments of Biotechnology and Pharmacy particularly on the subject of current scientific interest, and the proceedings of which will be published regularly. And in view of the vast development of science and to disseminate the problems in publication of research work, an international journal of Current Trends in Biotechnology and Pharmacy has been started by ABAP.